Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carlos F. M. Silva has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diketopyrrolopyrroles as promising acetylcholinesterase and butyrylcholinesterase inhibitors: In vitro and in silico studies

    by Carlos F.M. Silva, Vitor A.S. Almodovar, Vasco M.S. Castanheira, Florbela Pereira, Diana C.G.A. Pinto, Artur M.S. Silva, Augusto C. Tomé

  • Open Access

    Uncovering the Potential of Diketopyrrolopyrroles as First-In-Class Acetylcholinesterase and Butyrylcholinesterase Inhibitors Using In Vitro and In Silico Studies

    by Vitor AlmodÔVar, Carlos Silva, Vasco Castanheira, Amr El-Demerdash, Diana Pinto, Artur M. S. Silva, Augusto Tomé

    Alzheimer’s disease (AD) is an irreversible neurodegenerative disorder responsible for most age-associated dementias, causing memory loss and cognitive impairment. In the absence of an effective cure, the current AD treatments are mainly focused on symptom management, with most FDA-approved drugs for AD acting as acetylcholinesterase (AChE) inhibitors. Diketopyrrolopyrroles (DPPs) are a class of planar N-containing heterocycles widely explored as high-performance dyes and pigments. However, their biological potential remains largely underexplored, with applications mainly limited to photodynamic therapy (PDT), photodynamic inactivation (PDI) and fluorescent DNA biosensing. To the best of our knowledge, the present study is the first to describe the design, synthesis and evaluation of a series of eleven DPPs for their inhibitory activity against both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The results demonstrate that the DPP scaffold is a promising core for the development of novel AChE and BuChE inhibitors, yielding several submicromolar inhibitors of both enzymes. Among them, derivative 14 emerged as the most active DPP against both AChE (IC50 0.13 ± 0.03 µM) and BuChE (IC50 0.21 ± 0.02 µM). Molecular docking studies further corroborated the experimental results, supporting a dual-site binding mode for the most active derivatives, involving both the catalytic active site (CAS) and peripheral anionic site (PAS). Although preliminary physicochemical and ADMET evaluation highlights the need for further optimization, this work establishes DPPs as a novel scaffold for the development of dual and selective cholinesterase inhibitors and provides a foundation for future anti-AD drug discovery.

  • Open Access

    1,3,5-Triazine: A Promising Molecular Scaffold for Novel Agents for the Treatment of Alzheimer’s Disease

    by Carlos F. M. Silva, Ana P. D. de M. S. Guerrinha, Sofia Carvalho, Diana C. G. A. Pinto, Artur M. S. Silva

    Currently, Alzheimer’s disease (AD) is one of the most frequent forms of dementia. From a molecular perspective, the molecular characteristics that better define this disease consist of abnormal protein deposits between neuronal cells, namely senile plaques (SPs) and neurofibrillary tangles (NFTs), consisting of protein aggregates of amyloid-β and hyperphosphorylated tau protein, respectively. In addition to these protein aggregates, a third molecular hallmark of AD consists of depleted neurotransmitter acetylcholine levels. To date, the treatments developed for this disease are mostly focused on the use of AChE inhibitors, presenting only a symptomatic approach against the disease instead of a cure. Triazines are nitrogen-containing heterocyclic compounds that, throughout the years, have attracted a lot of curiosity from medicinal chemists for presenting numerous biological properties and being widely present in nature. In particular, this class of compounds has been associated with inhibiting several biological targets, emerging as a promising class for developing new pharmacological agents. However, there is still a scarcity of knowledge regarding the potential of this type of compound against any of the hallmarks of AD. For this reason, this paper intends to fulfill this absence by highlighting the potential of a subclass of triazines, 1,3,5-triazines (sym-triazines), as promising molecules for developing novel AD treatments. Thus, an in-depth analysis of 1,3,5-triazine derivatives is performed regarding its inhibitory activity against AChE (cholinergic hypothesis) and its capability to inhibit amyloid-β formation and aggregation (amyloid hypothesis). Through this analysis, it is possible to indicate some structural features optimal for each described activity, a compilation that we believe to be essential for the scientific community in this never-ending pursuit.


  • Open Access

    Design of Promising Thiazoloindazole-Based Acetylcholinesterase Inhibitors Guided by Molecular Docking and Experimental Insights

    by Fatima Ezzahra Laghchioua, Carlos F. M. da Silva, Diana C. G. A. Pinto, José A. S. Cavaleiro, Ricardo F. Mendes, Filipe A. Almeida Paz, Maria A. F. Faustino, El Mostapha Rakib, M. Graça P. M. S. Neves, Florbela Pereira, et al.

    Alzheimer's disease is characterized by a progressive deterioration of cognitive function and memory loss, and it is closely associated with the dysregulation of cholinergic neurotransmission. Since acetylcholinesterase (AChE) is a critical enzyme in the nervous system, responsible for breaking down the neurotransmitter acetylcholine, its inhibition holds a significant interest in the treatment of various neurological disorders. Therefore, it is crucial to develop efficient AChE inhibitors capable of increasing acetylcholine levels, ultimately leading to improved cholinergic neurotransmission. The results reported here represent a step forward in the development of novel thiazoloindazole-based compounds that have the potential to serve as effective AChE inhibitors. Molecular docking studies revealed that certain of the evaluated nitroindazole-based compounds outperformed donepezil, a well-known AChE inhibitor used in Alzheimer's disease treatment. Sustained by these findings, two series of compounds were synthesized. One series included a triazole moiety (Tl45a-c), while the other incorporated a carbazole moiety (Tl58a-c). These compounds were isolated in yields ranging from 66 to 87% through nucleophilic substitution and Cu(I)-catalyzed azide-alkyne 1,3-dipolar cycloaddition (CuAAC) reactions. Among the synthesized compounds, the thiazoloindazole-based 6b core derivatives emerged as selective AChE inhibitors, exhibiting remarkable IC50 values of less than 1.0 μM. Notably, derivative Tl45b displays superior performance as an AChE inhibitor, boasting the lowest IC50 (0.071 ± 0.014 μM). Structure-activity relationship (SAR) analysis indicated that derivatives containing the bis(trifluoromethyl)phenyl-triazolyl group demonstrated the most promising activity against AChE, when compared to more rigid substituents such as carbazolyl moiety. The combination of molecular docking and experimental synthesis provides a suitable and promising strategy for the development of new efficient thiazoloindazole-based AChE inhibitors.


  • Open Access

    Evolution of the Quinoline Scaffold for the Treatment of Leishmaniasis: A Structural Perspective

    by Carlos F. M. Silva, Diana C. G. A. Pinto, Pedro A. Fernandes, Artur M. S. Silva

    Since the beginning of the XXI century, Leishmaniasis has been integrated into the World Health Organization’s list of the 20 neglected tropical diseases, being considered a public health issue in more than 88 countries, especially in the tropics, subtropics, and the Mediterranean area. Statistically, this disease presents a world prevalence of 12 million cases worldwide, with this number being expected to increase shortly due to the 350 million people considered at risk and the 2–2.5 million new cases appearing every year. The lack of an appropriate and effective treatment against this disease has intensified the interest of many research groups to pursue the discovery and development of novel treatments in close collaboration with the WHO, which hopes to eradicate it shortly. This paper intends to highlight the quinoline scaffold’s potential for developing novel antileishmanial agents and provide a set of structural guidelines to help the research groups in the medicinal chemistry field perform more direct drug discovery and development programs. Thus, this review paper presents a thorough compilation of the most recent advances in the development of new quinoline-based antileishmanial agents, with a particular focus on structure–activity relationship studies that should be considerably useful for the future of the field.


  • Open Access

    Discovery of thiazolo[5,4-c]isoquinoline based compounds as acetylcholinesterase inhibitors through computational target prediction, molecular docking and bioassay

    by Letícia D. Costa, Carlos F.M. Silva, Diana C.G.A. Pinto, Artur M.S. Silva, Florbela Pereira, Maria Amparo F. Faustino, Augusto C. Tomé


  • Open Access

    Structure–Activity Relationship Studies of 9-Alkylamino-1,2,3,4-tetrahydroacridines against Leishmania (Leishmania) infantum Promastigotes

    by Carlos F. M. Silva, Teresa Leão, Filipa Dias, Ana M. Tomás, Diana C. G. A. Pinto, Eduardo F. T. Oliveira, Ana Oliveira, Pedro A. Fernandes, Artur M. S. Silva

    Leishmaniasis is one of the most neglected diseases in modern times, mainly affecting people from developing countries of the tropics, subtropics and the Mediterranean basin, with approximately 350 million people considered at risk of developing this disease. The incidence of human leishmaniasis has increased over the past decades due to failing prevention and therapeutic measures—there are no vaccines and chemotherapy, which is problematic. Acridine derivatives constitute an interesting group of nitrogen-containing heterocyclic compounds associated with numerous bioactivities, with emphasis to their antileishmanial potential. The present work builds on computational studies focusing on a specific enzyme of the parasite, S-adenosylmethionine decarboxylase (AdoMet DC), with several 1,2,3,4-tetrahydro-acridines emerging as potential inhibitors, evidencing this scaffold as a promising building block for novel antileishmanial pharmaceuticals. Thus, several 1,2,3,4-tetrahydroacridine derivatives have been synthesized, their activity against Leishmania (Leishmania) infantum promastigotes evaluated and a structure–activity relationship (SAR) study was developed based on the results obtained. Even though the majority of the 1,2,3,4-tetrahydroacridines evaluated presented high levels of toxicity, the structural information gathered in this work allowed its application with another scaffold (quinoline), leading to the obtention of N1,N12-bis(7-chloroquinolin-4-yl)dodecane-1,12-diamine (12) as a promising novel antileishmanial agent (IC50 = 0.60 ± 0.11 μM, EC50 = 11.69 ± 3.96 μM and TI = 19.48).


  • Open Access

    Evolution of Acridines and Xanthenes as a Core Structure for the Development of Antileishmanial Agents

    by Carlos F. M. Silva, Diana C. G. A. Pinto, Pedro A. Fernandes, Artur M. S. Silva

    Nowadays, leishmaniasis constitutes a public health issue in more than 88 countries, affecting mainly people from the tropics, subtropics, and the Mediterranean area. Every year, the prevalence of this infectious disease increases, with the appearance of 1.5–2 million new cases of cutaneous leishmaniasis and 500,000 cases of visceral leishmaniasis, endangering approximately 350 million people worldwide. Therefore, the absence of a vaccine or effective treatment makes the discovery and development of new antileishmanial therapies one of the focuses for the scientific community that, in association with WHO, hopes to eradicate this disease shortly. This paper is intended to highlight the relevance of nitrogen- and oxygen-containing tricyclic heterocycles, particularly acridine and xanthene derivatives, for the development of treatments against leishmaniasis. Thus, in this review, a thorough compilation of the most promising antileishmanial acridine and xanthene derivatives is performed from both natural and synthetic origins. Additionally, some structure–activity relationship studies are also depicted and discussed to provide insight into the optimal structural features responsible for these compounds’ antileishmanial activity.


  • Open Access

    A Valuable Method for the Synthesis of 2‐Benzylchromones: A Comparative Evaluation of Both Conventional and Microwave‐Assisted Synthesis

    by Carlos F. M. Silva, João A. Pacheco, Diana C. G. A. Pinto, Artur M. S. Silva

    Chromones (4 H ‐chromen‐4‐ones) contemplate a naturally occurring class of compounds widely distributed in Nature, particularly in plants. This singular ring system has emerged as a privileged scaffold in medicinal chemistry, mainly due to its unique structural features, diverse biological activities, and pharmacological properties. Throughout the past few years, our efforts have been focused on synthesizing a series of 2‐benzylchromones through a Claisen condensation, using 2’‐hydroxyacetophenones and ethyl 2‐phenylacetates. However, the extended periods of reaction necessary for the synthesis of 2‐benzylchromones led to the search for an alternative. Thus, microwave irradiation emerged as a suitable approach to obtain these chromones in shorter reaction times and with similar or even improved synthetic yields. Our work demonstrates that it is possible to synthesize 2‐benzylchromones through both conventional and microwave‐assisted synthesis, favoring the use of microwave irradiation.


  • Chromones: privileged scaffolds for the production of multi-target-directed-ligand agents for the treatment of Alzheimer’s disease

    by Carlos F. M. Silva, Diana C. G. A. Pinto, Artur M. S. Silva

    Introduction: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder responsible for the great majority of age-related dementias affecting daily life through memory loss and cognitive impairment. From a molecular point of view, the most common neuropathological characteristics found in AD patients are abnormal protein deposits, particularly senile plaques (SP) and neurofibrillary tangles (NFT). Furthermore, the currently available pharmacological treatment only provides short-term improvements and is focused on the use of cholinesterase (ChEs) inhibitors or memantine, an approved medicine that is a glutamatergic N-methyl-D-aspartate (NMDA) receptor blocker. Areas covered: This review is focused on the relevance of chromones for future AD treatment. Structure-activity relationship (SAR) studies which look at the inhibition of amyloid-β (Aβ) plaque formation and aggregation and the inhibition of both acetylcholinesterase (AChE) and butyrylcholinesterase are also discussed. Expert opinion: SAR studies are a useful strategy for the elucidation of structural features that improve compound-specific AD-related activities. The development of multi-target-directed ligands (MTDLs) represents an exciting challenge for organic chemists. As such, recently developed chromone-type compounds have a potential use as MTDLs for the treatment of AD.